20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Organon & Co (OGN) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Jersey City, United States with about 10,000 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, OGN reported $6.2B in revenue and $187M in net income.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Interactive charts & full statements → Open the OGN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $6.1B | $6.2B | $6.4B | $6.3B | $6.2B | $6.3B | $6.5B | $7.8B | $9.8B | $10.5B |
| Gross Profit | $3.2B | $3.4B | $3.7B | $3.7B | $3.9B | $3.9B | $4.4B | $5.5B | $5.1B | $5.9B |
| Gross Margin % | 53.0% | 54.1% | 58.0% | 59.8% | 62.8% | 62.2% | 67.6% | 70.8% | 52.0% | 56.3% |
| Operating Income (EBIT) | $1.2B | $1.3B | $1.5B | $1.3B | $1.7B | $1.9B | $2.8B | $3.8B | $2.7B | $3.3B |
| Operating Margin % | 19.3% | 20.7% | 23.2% | 21.2% | 27.6% | 30.4% | 43.6% | 49.5% | 27.7% | 31.2% |
| Net Income | $209M | $187M | $864M | $1.0B | $917M | $1.4B | $2.2B | $3.2B | $2.2B | $1.8B |
| Net Margin % | 3.4% | 3.0% | 13.5% | 16.3% | 14.8% | 21.4% | 33.1% | 41.4% | 22.0% | 17.2% |
| EBITDA | $1.3B | $1.3B | $1.6B | $1.4B | $1.8B | $2.0B | $3.0B | $3.9B | $4.4B | $5.1B |
| Earnings Per Share (EPS) | $0.78 | $0.72 | $3.33 | $3.99 | $3.59 | $5.33 | $8.52 | $12.71 | $8.51 | $7.11 |
| Shares Outstanding (M) | 270M | 261M | 259M | 256M | 255M | 254M | 254M | 253M | 253M | 253M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.6B | $1.5B | $1.5B | $1.6B | $1.6B | $1.5B | $1.6B | $1.6B |
| Gross Profit | $847M | $783M | $759M | $857M | $874M | $841M | $896M | $923M |
| Gross Margin % | 54.4% | 53.6% | 50.4% | 53.5% | 54.8% | 55.6% | 56.3% | 58.3% |
| Operating Income (EBIT) | $323M | $266M | $235M | $358M | $326M | $325M | $296M | $390M |
| Operating Margin % | 20.7% | 18.2% | 15.6% | 22.4% | 20.4% | 21.5% | 18.6% | 24.6% |
| Net Income | $108M | $146M | ($205M) | $160M | $145M | $87M | $109M | $359M |
| Net Margin % | 6.9% | 10.0% | -13.6% | 10.0% | 9.1% | 5.8% | 6.9% | 22.7% |
| EBITDA | $371M | $410M | $65M | $460M | $449M | $325M | $341M | $402M |
| Earnings Per Share (EPS) | $0.40 | $0.56 | $-0.79 | $0.61 | $0.56 | $0.33 | $0.42 | $1.38 |
| Shares Outstanding (M) | 270M | 263M | 260M | 261M | 260M | 261M | 260M | 260M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $737M | $700M | $939M | $799M | $858M | $2.5B | $2.2B | $2.8B | $3.7B | $3.4B |
| Capital Expenditures (CapEx) | $239M | $162M | $351M | $261M | $427M | $488M | $278M | $92M | $101M | $86M |
| Free Cash Flow (FCF) | $498M | $538M | $588M | $538M | $431M | $2.0B | $1.9B | $2.7B | $3.6B | $3.3B |
| FCF Margin % | 8.1% | 8.7% | 9.2% | 8.6% | 7.0% | 31.2% | 29.2% | 34.4% | 36.7% | 31.7% |
| Dividends Paid | $18M | $88M | $297M | $294M | $290M | $145M | $145M | $145M | $145M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $107M | $225M | $141M | $264M | $220M | $75M | $390M | $141M |
| Capital Expenditures (CapEx) | $42M | $37M | $45M | $115M | $39M | $97M | $132M | $76M |
| Free Cash Flow (FCF) | $65M | $188M | $96M | $149M | $181M | ($22M) | $258M | $65M |
| FCF Margin % | 4.2% | 12.9% | 6.4% | 9.3% | 11.4% | -1.5% | 16.2% | 4.1% |
| Dividends Paid | $6M | $5M | $4M | $3M | $10M | $71M | $74M | $74M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.2B | $12.9B | $13.1B | $12.1B | $11.0B | $10.7B | $10.1B | $10.5B | $10.5B |
| Cash & Cash Equivalents | $1.1B | $574M | $675M | $693M | $706M | $737M | $12M | $319M | $244M |
| Total Liabilities | $12.2B | $12.1B | $12.6B | $12.1B | $11.8B | $12.2B | $4.6B | $3.5B | $4.1B |
| Total Debt (Short + Long-Term) | $8.6B | $8.7B | $8.9B | $8.8B | $9.0B | $9.2B | $8M | $118M | ($173M) |
| Total Shareholders' Equity | $1.0B | $752M | $472M | ($70M) | ($892M) | ($1.5B) | $5.5B | $7.0B | $6.3B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OGN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms